Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Whole-cell versus acellular pertussis booster vaccines in 4-year-old children
NL-OMON25000Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Mar 1998
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of whole-cell pertussis vaccine, acellular pertussis vaccine, diphtheria-tetanus-inactivated poliovirus vaccine, DTwP-IPV vaccine and Polimilex in pertussis (5 arms), sponsored by National Institute for Public Health and the Environment. Primary endpoint: Pertussis immunogenicity. Started Mar 1998; status: active, not recruiting.
02
Drugs
whole-cell pertussis vaccineacellular pertussis vaccinediphtheria-tetanus-inactivated poliovirus vaccineDTwP-IPV vaccinePolimilex
03
Conditions
pertussis
Beyond the preview
Go deeper on NL-OMON25000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25000.